Type: Public
On the web: http://www.angiotech.com
Employees: 1,368
Employee growth: 1.3%

Angiotech Pharmaceuticals is teaching old devices new tricks. It develops medical products that combine devices with drugs to make them more effective. Its flagship product in the Pharmaceutical Technologies segment is the TAXUS drug-eluting stent, which Boston Scientific sells and for which it pays Angiotech royalties. The company's Medical Products segment makes the Quill wound closure system and other single-use medical products for interventional radiology, ophthalmology, and surgery. Angiotech received bankruptcy protection from its creditors under Canada's Companies' Creditors Arrangement Act.

Key numbers for fiscal year ending December, 2010:
Sales: $246.2M
One year growth: (12.0%)
Net income: ($66.8)M

Officers:
Chairman: David T. Howard
President, CEO, and Director: William L. Hunter
CFO: K. Thomas (Tom) Bailey

Competitors:
Cardinal Health
Covidien
Bard